Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics license application ((sBLA)) for Eylea HD injection, 8 mg, to treat macular ...

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Currently, EYLEA HD is approved for dosing intervals of 8-16 weeks for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). For patients with diabetic ...

Q1 2025 Management View CEO Leonard Schleifer highlighted mixed performance in Q1 2025, with challenges in the retinal ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it ...

Regeneron Pharmaceuticals Inc (REGN) reports robust growth in Dupixent sales and strategic R&D investments, while navigating ...

Regulatory delays impacting EYLEA HD’s pre-filled syringe approval could hinder adoption. Increased market share of off-label Avastin poses a challenge to the anti-VEGF category. Analysts raised ...